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Summary
Vertebrate members of the nuclear receptor NR5A sub-
family, which includes steroidogenic factor 1 (SF-1) and
liver receptor homolog 1 (LRH-1), regulate crucial as-
pects of development, endocrine homeostasis, and
metabolism. Mouse LRH-1 is believed to be a ligand-
independent transcription factor with a large and
empty hydrophobic pocket. Here we present struc-
tural and biochemical data for three other NR5A mem-
bers—mouse and human SF-1 and human LRH-1—
which reveal that these receptors bind phosphatidyl
inositol second messengers and that ligand binding
is required for maximal activity. Evolutionary analysis
of structure-function relationships across the SF-1/
LRH-1 subfamily indicates that ligand binding is the
ancestral state of NR5A receptors and was uniquely
diminished or altered in the rodent LRH-1 lineage. We
propose that phospholipids regulate gene expression
by directly binding to NR5A nuclear receptors.
Introduction
Unlike most nuclear receptors, which are regulated by
steroid, retinoid, and other nonpolar ligands, NR sub-
family 5A are constitutively active in many cell types,
and obvious ligand candidates have not been forth-
coming. SF-1 (NR5A1) orchestrates endocrine tissue
development and male sexual differentiation and con-*Correspondence: hollyi@itsa.ucsf.edu
7 These authors contributed equally to this work.trols steroid biosynthesis (Ingraham et al., 1994; Luo et
al., 1994). LRH-1 (NR5A2) is essential in early develop-
ment and regulates bile acid synthesis, cholesterol
transport, and ovarian function (Fayard et al., 2004; Lu
et al., 2000). This subfamily is distinct in that members
are able to bind as monomers to DNA, and they pos-
sess an unusually large hinge domain that is subject to
posttranslational modifications, including phosphoryla-
tion and sumoylation (Desclozeaux et al., 2002; Lee et
al., 2005). Although physiological roles for these recep-
tors have emerged, ligand candidates have remained
controversial. The proposed SF-1 ligand 25-hydro-
xycholesterol, while appealing because of the recep-
tor's regulation of steroid synthesis, appears to be in-
correct because oxysterols fail to activate SF-1 in most
cell lines (Christenson et al., 1998; Lala et al., 1997; Mel-
lon and Bair, 1998). Further, the notion that ligands
might be dispensable for this subfamily of receptors
was bolstered by the crystal structure of mouse LRH-1
ligand binding domain (LBD), showing an active confor-
mation in the absence of either ligand or coregulator
peptide. Unlike other orphan nuclear receptors, which
either lack a ligand binding pocket (e.g., Nurr1, DHR38,
or ERRα) or have a constitutively bound lipid (e.g.,
HNF4α, HNF4γ, or USP), mLRH-1 was found to possess
a large unoccupied hydrophobic pocket ofw830 Å (re-
viewed in Li et al. [2003]). Remarkably, mutations that
filled the mLRH-1 pocket failed to reduce transcrip-
tional activity (Sablin et al., 2003).
Whereas an elegant structural paradigm has devel-
oped to explain the activation of ligand-regulated re-
ceptors, no uniform mechanism has been proposed to
account for the modulation of orphan nuclear receptor
activity (Steinmetz et al., 2001; Weatherman et al.,
1999). The presence of fortuitous lipid molecules re-
vealed in crystallization experiments can be associated
with an inactive LBD conformation as noted for the
dipterian USP LBD (Billas et al., 2001). On the other
hand, lipid components have been proposed to stabi-
lize an active LBD conformation in constitutively active
nuclear receptors, with HNF4 binding fatty acids (Dhe-
Paganon et al., 2002; Wisely et al., 2002) and RORα
binding cholesterol (Kallen et al., 2002). In this context,
the structure of the murine LRH-1 with its empty ligand
binding pocket remains a puzzle. To further explore
how NR5A orphan receptors are regulated, we obtained
the LBD crystal structures of other members of this
subfamily, including mSF-1, hSF-1, and hLRH-1. Here
we provide structural and biochemical data supporting
ligand regulation for NR5A orphan nuclear receptors.
Results and Discussion
NR5A Structures Reveal a Phospholipid
in the Ligand Binding Pocket
The structure of mSF-1 was determined by the molecu-
lar replacement method using the atomic coordinates
from Protein Data Bank entry 1PK5 for the mLRH-1 LBD
coordinates (Sablin et al., 2003). Two hSF-1 structures
Cell
344were obtained, with and without TIF-2 peptide, and t
were determined by MAD and SAD methods using sele- l
nomethionine substituted proteins, respectively (Mad- s
auss et al., 2004). The structure of hLRH-1 was det- w
ermined by molecular replacement using the atomic d
coordinates for hSF-1. The current best structures are D
refined to 1.2 Å, 2.5 Å, and 2.5 Å for mSF-1, hLRH-1, and p
hSF-1, respectively. Relevant features of data collection o
and refinement statistics for each protein crystal are s
provided in Table 1. All three LBDs exhibit a character- p
istic protein fold noted for other LBDs, with 12 α heli- a
ces, two β strands, and helix H12 positioned in an H
active conformation (Figure 1). A fourth layer is pro- l
vided by a structured helix H2, as previously shown for t
mLRH-1, although the position and length of this helix
are the most varied features as judged by comparison t
of mSF-1 with hSF-1 LBD (Figure 1C) and mLRH-1 with l
hLRH-1 (Figure 1D). Upon refinement of these three p
LBD structures, additional electron density was present
h
in the ligand binding pockets consistent with the pres-
C
ence of a phospholipid; the presence of ligand con-
2trasts the reported structure of mLRH-1 showing no
sdensity inside or at the opening of the pocket.
dThe nature of this phospholipid was further charac-
tterized by nondenaturing mass spectrometry of LBD
aproteins used for crystallization. Spectra were consis-
Ltent with two principle series of ions consisting of both
lligand bound and apo-proteins. Comparison of all four
tLBD protein solutions showed the presence of phos-
lpholipid in SF-1 and hLRH-1 but with a much lower
lconcentration in mLRH-1 where only w10% is bound
Nby ligand (Figures 2A and 2B and Supplemental Figure
sS1 available with this article online). Quantitation of
ahLRH-1 and mSF-1 bound by phospholipid showed a
i1:1 ligand/receptor complex with nearly all of the pro-
btein bound by a phospholipid. The lower levels of phos-
ipholipid bound to bacterially expressed mLRH-1 LBD
are consistent with the absence of electron density in sTable 1. Data Collection and Refinement Statistics
Crystallization mSF-1/mSHP-1 hSF-1/No Pep. hSF-1/TIF-2 hLRH-1/TIF-2
Unit Cell Dimensions
a (Å) 73.9 128.4 73.1 59.9
b (Å) 73.9 66.0 73.1 67.2
c (Å) 117.0 141.0 139.4 79.6
Space group P41212 P21 P41212 P212121
Molecules per asymmetric unit 1 7 1 1
Resolution (Å) 25–1.2 20–2.5 20–2.9 40–2.5
Number of unique reflections 100,431 71,698 15,614 10,787
Data redundancy 13.1 2 8 6
Completeness (%) 99.9 97.9 99.8 91.9
Rsymm (%) 6.1 4.5 5.8 3.7
< I/s(I) > 39.2 28.0 30.0 44.0
Refinement
R 19.7 24.9 24.6 23.2
Rfree 21.1 28.3 29.0 28.3
Rms deviation from ideality
Bond length (Å) 0.012 0.009 0.011 0.008
Bond angle (0) 1.483 1.20 1.34 1.349
Average B factor (A2)
All atoms 22.8 85 62 64.4
Protein atoms 21.3 85 61 63.9
Water molecules 25.7 78 55 60.5he pocket of the mLRH-1 LBD structure. Of possible
igands ranging from 680–780 Da, the most prominent
pecies were found to be 747 and 721 Da, consistent
ith two common bacterial phospholipids, phosphati-
yl glycerol (PG) and phosphatidyl ethanolamine (PE).
enaturing negative electrospray ionization assigned the
rominent ligand species as PG (Figure 2C); confirmation
f this assignment was provided by the atomic crystal
tructure of mSF-1, where the head group of the phos-
holipid was determined to be glycerol rather than eth-
nolamine (Figure 2D). Mutating Ala270 to Trp in helix
3 of mSF-1, which would fill the pocket and disfavor
igand binding, eliminates all detectable PG ligand from
he pocket by mass spectrometry (A270W, Figure 2B).
Electron densities maps of mSF-1 or hSF-1 (± TIF pep-
ide) showed nearly identical conformation of a phospho-
ipid containing two fatty acid chains (C16 and C18) occu-
ying nearly the entire hydrophobic pocket; only
ydrophobic interactions are observed between the
16 and C18 chains and surrounding residues (Figures
D, 2E, and Supplemental Table S1). Atomic resolution
tructure of mSF-1 LBD confirmed the presence of
ouble bonds at the C9 position in both chains within
he bound phospholipid. The large pocket sizes of hSF-1
nd hLRH-1 are similar to that reported for the mLRH-1
BD, easily accommodating two tails of the phospho-
ipid. In hLRH-1, the ligand adopts a similar conforma-
ion or path as found for SF-1; however, the density is
ess ordered and the lower resolution prevented abso-
ute assignment of the head group (data not shown).
onetheless, we find that all phosphates are positioned
imilarly in the mouth of the pocket for mSF-1, hSF-1,
nd hLRH-1. Although a phospholipid ligand is present
n both USP and NR5A, the consequences of ligand
inding differ greatly, with ligand proposed to drive USP
nto an antagonist conformation, rather than the agonist
tate observed for NR5A receptors (Billas et al., 2001).
Phospholipids as NR5A Receptor Ligands
345Figure 1. NR5A LBD Receptors Structures Reveal a Ligand
(A and B) Two views of mouse SF-1 (mSF-1) LBD protein are shown (red, orange, and brown ribbons) with all twelve α helices and the single
β turn indicated in panels. Helix H2 is highlighted in bright red (H2). The corepressor peptide form the N-terminal portion of mSHP is shown
in the AF2 cleft just adjacent to helix H12 (SHP-1, turquoise ribbon). The presence of a ligand determined to be phosphatidyl glycerol (PG) is
also shown in the hydrophobic pocket (blue stick).
(C) The model for human SF-1 (hSF-1, dark red ribbons) superposed with the mSF-1 (light red) is shown.
(D) The human LRH-1 LBD (hLRH-1, orange ribbons) superposed with the mouse LRH-1 LBD (yellow ribbons) structure is shown. Helices H2,
H9, and H12 are indicated in both structures, with H2 highlighted in red for all LBDs. For both hSF-1 and hLRH-1, the TIF-2 peptide bound
structures are shown (refer to Table 1), and the phospholipid is indicated (PG, blue stick).Phosphatidyl Inositol Phosphates Are Selectively
Bound by SF-1 and hLRH-1
While our structural studies indicate that bacterially ex-
pressed SF-1 and LRH-1 can bind to phospholipids, the
nature of a bona fide ligand in eukaryotic cells remains
unknown. We tested the ability of mSF-1 to bindeukaryotic phospholipids, including phosphatidyl inosi-
tols (PIs), using immobilized lipids on nitrocellulose, as
described in Experimental Procedures. Of the common
eukaryotic phospholipids, mSF-1 and hLRH-1 selec-
tively bound the PIP2 and PIP3 phosphatidyl inositol
species 2- to 3-fold better than the pocket mutant pro-
Cell
346Figure 2. Binding of Phospholipids by SF-1s and hLRH-1 Is Greater than for mLRH-1 or for the mSF-1 A270W Pocket Mutant
(A) Nondenaturing mass spectrometry was carried out on all four LBD proteins used for crystallization (mSF-1, hSF-1 and mLRH-1, hLRH-1).
Spectra are shown for mLRH-1 (left panel) and mSF-1 (right panel), with the apo [A], and the bound [B] species indicated. The molecular
weight difference between the two peaks is also shown (arrow).
(B) The concentrations of all bound LBD species, including the mSF-1 A270W pocket mutant, were determined as described and are listed
for equal amounts of LBD protein (w30 µM), with the exception of hSF-1, where more protein was used due to the poorer quality of protein
(50 µM).
(C) Product ions following collision-induced decomposition using denaturing electrospray tandem mass spectrometry (ESI MS/MS) on m/z
745 (blue diamond) are shown for hSF-1 and reveal a phosphatidyl glycerol (chemical structure) ligand with two acyl chains of C16 and C18.
(D) Electron density for mSF-1 is from a 2Fo−Fc map contoured at 1.2 sigma that shows the phospholipid ligand flanked by surrounding
residues (sticks). Three residues are labeled: Gly342, Tyr437, and Ala270, and the phosphate in the PG ligand is indicated (P).
(E) Electron density found for both mSF-1 (blue) and hSF-1 ± TIF peptide (white or gray) ligands are superposed showing an identical position
in the hydrophobic ligand binding pocket.tein (A270W, Figure 3A), with signals being especially s
ostrong for both PI(3,5)P2 and PI(3,4,5)P3. Both wild-type
and mutant mSF-1 protein bound equally to PA or the w
psingle phosphorylated PIPs, suggesting that these neg-
atively charged lipids bound to the solvent-exposed hurface of the LBD. More importantly, equal amounts
f incubated apo human PPARγ-LBD displayed much
eaker binding with a different profile (Figure 3A, right
anel), and no binding was detected with liganded
TRβ LBD (data not shown). The capacity to bind such
Phospholipids as NR5A Receptor Ligands
347Figure 3. Selective Binding to Phosphorylated Phosphatidyl Inositols by mSF-1 and Loss of Activity with mSF-1 Pocket Mutant
(A) Binding patterns to immobilized phospholipids for mSF-1, the mSF-1 A270W pocket mutant, hLRH-1, and a control protein apo-hPPARγ
are shown with the identity of each phospholipid indicated. Levels of all four proteins incubated were equivalent (data not shown). Quantifica-
tion of binding by wild-type mutant mSF-1 LBD protein (A270W) showed selective binding to all PIP2 and PIP3 species by 1.85- to 3.1-fold.
Abbreviations are as follows: lysophosphatidic acid (LPA), lysophosphocholine (LPC), sphingosine-1-phosphate (SIP), phosphatidic acid (PA),
phosphatidyl choline (PC), serine (PS), ethanolamine (PE), phosphatidyl inositol (PI), phosphatidyl (3), (4), or (5) inositiol monophosphate (P3I),
(P4I), or (P5I), phosphatidyl (3,4), (3,5), or (4,5) inositol bisphosphate (P3,4I), (P3,5I) (P4,5I), and finally phosphatidyl (3,4,5) inositol triphosphate
(PIP3). Chemical structures are shown for PA and P3,4,5I.
(B) Activities of pocket mutants made in comparable positions in helix H3 for mSF-1 (A270W mSF-1) are shown following transfections in
HepG2 human cells with two luciferase reporters, the aromatase, and mouse SHP promoters. Relative luciferase activities are shown as fold
activation for each receptor at increasing concentrations (ng per 24 well plate), as indicated on the X axis.
(C) The luciferase activity is shown for the corresponding helix H3 A368W pocket mutant for mLRH-1 on the aromatase promoter in HepG2
cells.ligands appears critical for mSF-1 activity as evidenced
by the diminished activity exhibited by A270W mSF-1
pocket mutant (Figure 3C, refer back to Figure 2B). Thissame mutation when made in mLRH-1 (A368W, H3)
caused little or no loss of activity in cellular assays, as
previously observed (Figure 3C and Sablin et al. [2003]).
Cell
348The binding of phospholipids was further explored u
tby mass spectrometry analysis of purified LBD proteins
after incubation with liposomes containing phosphati- L
rdyl choline (PC), mixed with either phosphatidic acid
(PA), PI(3,4)P2, or PI(3,4,5)P3 in a 9:1 ratio. Remarkably, e
lincubation of the mSF-1 LBD with the neutral PC lipo-
some showed an almost complete loss of the bacterial l
aPG phospholipid with very little exchange or binding by
PC; similar results were found with the PC:PA liposome e
P(Figures 4B and 4C) with both profiles differing greatly
from spectra observed with the PG bound state of the m
omSF-1 LBD (Figure 4A, No Liposomes). In contrast, effi-
cient binding was observed for PI(3,4)P2 or PI(3,4,5)P3 r
Sas evidenced by the increase mass of 970 and 1050 Da,
respectively, with only a small uptake of PC observed m
(Figures 4D and 4E). A similar experiment carried out p
with mLRH-1 LBD revealed less selectivity compared i
to that of mSF-1, with equal exchange of PC, PI(3,4)P2, m
or PI(3,4,5)P3, as well as some liganded PA detected
(see Supplemental Figure S2). These data taken to- S
gether with the PIP strip binding data suggest that SF- h
1s and hLRH-1 bind much more robustly and selec- a
tively to phosphorylated PIs than does mLRH-1. The t
structural basis for this species difference in selective n
phospholipid binding is discussed below. t
h
FRegulation of NR5 Receptors Activity
NR5A receptors are coexpressed with and repressed w
iby the orphan nuclear receptors, Dax-1 and SHP (Fig-Figure 4. Selective Binding of Phosphatidyl Inositols to mSF-1
In the upper left corner, a flow diagram is shown for ligand analyses of mSF-1 LBD protein following incubation with different liposomes, as
described in Experimental Procedures. Mass spectra profiles (ESI-LC/MS) are shown for the basal state (No Liposomes, panel A), and after
incubations with the neutral liposomes of phosphatidyl choline (PC, panel B), with phosphatidic acid liposomes (PC:PA [9:1], panel C), and
with phosphatidyl inositol liposomes PC:PI(3,4)P2 [9:1] (PIP2, panel D) or PC:PI(3,4,5)P3 [9:1] (PIP3, panel E). In (B), (D), and (E), the small
peaks at mass 28730 Da are PC liganded receptor (PC), and in (C), the peak at mass 28646 is PA liganded receptor (PA). Direct mass
spectrometry analysis (without gel filtration) on the PC:PA-receptor sample revealed a strong peak of free phosphatidic acid (data not shown),
showing that ample PA was present in the PC:PA liposomes.re 5A). These orphan nuclear receptors contain a pu-
ative LBD but no DBD; their capacity to repress SF-1,
RH-1, and steroid hormone receptors is mediated by
egions within the very N- and C-terminal LBD (Holter
t al., 2002; Ito et al., 1997; Nachtigal et al., 1998). Un-
ike NR4 orphan receptors (Nurr1, DHR38) that have
ost their coactivator cleft (Baker et al., 2003; Wang et
l., 2003), all four LBD structures of SF-1 and LRH-1
xhibit a well-formed docking site for coregulators.
eptide binding assays were carried out for both
LRH-1 and mSF-1 LBD proteins using C-terminal flu-
rescently tagged SHP and Dax-1 peptides and fluo-
escence anisotropy, as described (Moore et al., 2004).
elective high-affinity binding was found for both
LRH-1 and mSF-1, with SF-1 binding more tightly to
eptides from Dax-1; only the N-terminal LXXLL motif
n the Dax-1 LBD region is able to bind both mSF-1 and
LRH-1 (Figures 5A and 5B).
As observed with NR/coactivator complexes, bound
HP-1 peptide in the coactivator cleft is positioned by
ydrophobic contacts between the peptide leucines
nd LBD surface residues, and by hydrogen bonds be-
ween the backbone carbonyl and the conserved argi-
ine (mArg282, hArg281), and the backbone amide with
he conserved glutamate (mGlu455, hGlu454) found in
elices H4 and H12, respectively (Figure 5C, left panel).
urther, superposition of the mSF-1/SHP-1 structure
ith the apo-structure of mLRH-1 shows little change
n the positions of helices H3, H4, and H12 contacting
Phospholipids as NR5A Receptor Ligands
349Figure 5. SHP and Dax-1 Binding to mSF-1
and mLRH-1
(A) Schematics of SHP and Dax-1 are shown
with colored boxes corresponding to LXXLL
peptides used in the fluorescence anisot-
ropy assay, as depicted and listed in the
table.
(B) Relative binding affinities for labeled pep-
tides are indicated by color-coded affinities
(Kd values) ranging from 0.5–10.0, 10.1–30.0,
and >30.0 µM and were determined as de-
scribed in Experimental Procedures. The
mSHP-1 peptide used in crystallization of
mSF-1 is RPTILYALLSPSPR (mSHP-1).
(C) Ribbon depiction of the mSHP-1 peptide
in the coactivator cleft of mSF-1 (orange rib-
bon) or superposed with the mLRH-1 struc-
ture (beige ribbon). Residues are numbered
according to the database entry Q62227 for
mSHP.the peptide (Figure 5C, right panel). Similarly, confor-
mations of LBDs and ligands were found to be nearly
identical when hSF-1 was crystallized with or without
TIF-2 (Figures 1C and 2E). Taken together, these data
suggest that selectivity of corepressor (Dax-1 and SHP)
or coactivator binding to NR5A receptors is mediated
by flanking amino acids. Moreover, NR5A receptors
adopt a seemingly “active conformation” at all times,
as opposed to classic ligand-dependent receptors
(Darimont et al., 1998). Activity levels achieved by this
class of receptor would then depend on ligand, post-
translational modifications, and levels of coregulators.
Thus, simply increasing corepressor levels, such as
Dax-1, may override ligand-dependent activation and
shift the receptor into an inactive state. This notion is
partially supported by genetic data showing dosage of
Dax-1 to be critical in mammalian sexual development,
where SF-1 regulates multiple genes (reviewed in Lud-
brook and Harley, 2004), and by the fact that SF-1 andLRH-1 regulate Dax-1 and SHP in a negative feedback
regulatory mechanism (Lu et al., 2000).
Compared with LRH-1, SF-1 exhibits a shorter helix
H2 and a more flexible region connecting helices H2
and H3 (Figure 6A). The mutation R314M, predicted to
disrupt a 2.7 Å salt bridge between Arg314 (H5) and
Glu238 (H2) in mSF-1 but not to interfere with ligand
binding, sharply diminished receptor activity (Figure
6B), suggesting that the integrity of the NR5 receptors
is mediated in part by packing interaction between he-
lix H2 and other helices in the body of receptor. Inter-
estingly, this same mutation when made in mLRH-1
(R412M) showed a much more modest decrease than
observed with the analogous SF-1 R314M mutant—in
mLRH-1 this interaction with corresponding shorter
side chain of Asp236 is predicted to be less important,
suggesting that additional interactions at the more ex-
tended H2-H3 interface in LRH-1 help to stabilize the
receptor structure.
Cell
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Figure 6. The Role of H2/H3 Structural Elements in Maintaining an
tActive Conformation of mLRH-1 and mSF-1
iIn the top panel, ribbon diagrams of partial structures of mLRH-1
band mSF-1 are shown. Helices H2 (red) and H3 (pink) of mSF-1 are
esuperposed with the helices H2 and H3 of mLRH-1 (light yellow),
and the phosphatidyl glycerol ligand is shown (blue stick). The H2 e
of mSF-1 is approximately half the length of helix H2 in mLRH-1 c
H2. The bottom panel shows reporter activity in HepG2 cells with l
increasing concentrations of wild-type and helix H5 mutants for
iboth mLRH-1 and mSF-1. Relative luciferase activities are shown.
a
h
cSpecies Difference in the Ligand Binding Pocket
The structures of NR5A receptors allow us to identify w
dspecific elements that facilitate phospholipid binding in
the mouse and human SF-1s and human LRH-1 but di- b
qminish it in mouse LRH-1. For all receptors, only hy-
drophobic interactions are made between the 33 residues d
tcontacting the PG phospholipid; residues contacting the
ligand are listed for all four LBDs (Supplemental Table m
cS1). Direct comparison of these residues shows con-
served changes between SF-1 and LRH-1, with most p
cdifferences adding mass to unoccupied space in the
mLRH-1 ligand-free pocket. However, when comparing h
species, a cluster of nonconserved residue changes
that span helices H6-H7 is noted between human and t
smouse LRH-1 (Figure 7A); on the other hand, only one
residue difference occurs between mouse and human NF-1. Further analysis shows residues within this clus-
er to be crucial for phospholipid binding. Indeed, bind-
ng of this ligand is optimized by coordination of the
hosphate head group at the base of the pocket, with
ydrogen bonding provided by Gly342 at the beginning
f H6, and Tyr437 and Lys441 at the end of H11, which
re 2.8 Å, 2.6 Å, and 2.8 Å from the ligand, respectively
Figure 7B). These interactions effectively seal the bot-
om of the ligand binding pocket with the phosphate
roup from the ligand contributing to this closure (Fig-
re 7C).
A different scenario occurs in mLRH-1, where Glu440
orms a strong ionic interaction with the opposing
ys539 in helix H11 (analogous to Lys441 in mSF-1),
ealing the pocket and stabilizing the mLRH-1 LBD in
he absence of the ligand (Figure 7C). The other unique
esidues spanning helices H6-H7 in mLRH-1 (Thr439
nd Phe443, Figure 7A) are also predicted to minimize
igand binding by clashing with both the phosphate
roup and aliphatic chains, respectively. To test the hy-
othesis that key residues interacting with the lipid’s
hosphate group are critical to ligand binding, mLRH-1
as “humanized” by an E440G mutation. Wild-type and
utant receptors were assayed before and after reduc-
ng cellular pools of phosphatidic acid and subsequent
hosphatidyl inositols with a competitive inhibitor of
hospholipase D (Fang et al., 2001). N-butanol treat-
ent had a marginal effect on the activity of mLRH-1
ut substantially reduced activation by the humanized
440G mLRH-1, and to a lesser extent wild-type mSF-1
Figure 7D). Collectively, these data are consistent with
he lowered selectively observed for mLRH-1 phospho-
ipid binding and are predicted by structures of the
RH-1 and SF-1 orthologs.
ecent Divergence in the Rodent LRH-1
volutionary analysis of structure-function relations in
he LRH-1/SF-1 subfamily indicates that ligand binding
s the ancestral state for these proteins where ligand
inding was subsequently reduced or altered in the lin-
age leading to the rodent LRH-1. We coded the pres-
nce or absence of ligand binding as a phylogenetic
haracter and reconstructed its evolution on the phy-
ogeny of the NR5A gene family (Figure 8). As described
n Experimental Procedures, both maximum parsimony
nd maximum likelihoods were used to evaluate two
ypotheses concerning the function of the common an-
estor of the entire NR5A subfamily—that the ancestor
as liganded (H1) and that it was unliganded (H0). Un-
er H1, a single loss of ligand binding is required on the
ranch leading to the rodent LRH-1, whereas H0 re-
uires ligand binding to have been gained indepen-
ently in the SF-1 and human LRH-1 lineages. H1 is
herefore the most parsimonious hypothesis. A maxi-
um likelihood analysis assuming that ligand binding
an be gained or lost under a simple reversible Markov
rocess also supports H1, albeit nonsignificantly, indi-
ating a loss of ligand binding in rodent LRH-1s (likeli-
ood ratio = 3.05).
To increase the power of our analysis, we analyzed
he evolution of the key sequence sites that have been
tructurally identified as critical for ligand binding in
R5A receptors. Although functional data from structures
Phospholipids as NR5A Receptor Ligands
351Figure 7. Species Differences in the Closure
of the Ligand Binding Pocket
(A) Sequence alignment of the region span-
ning helices H6 and H7 is shown for a limited
number of species. Rodent LRH-1-specific
changes are highlighted in red.
(B) Electron density showing coordination of
the phosphate group by three residues in
mSF-1. These include Gly342 (H7) and Tyr437
and Lys441 (H11) with hydrogen bonds indi-
cated (dashed line). The phosphate is la-
beled (P).
(C) Interactions between helices H7 and H11
are depicted for mSF-1, with phospholipid li-
gand (white stick) and for mLRH-1 without
ligand. The salt bridge between Glu440 and
Lys539 in mLRH-1 is depicted.
(D) Reporter activity is shown after depletion
of phosphatidic acid by butanol with wild-type
mLRH-1, mSF-1, and “humanized” mLRH-1
E440G mutant transfected into HepG2 cells.
Activity is expressed as fold activation using
the aromatase luciferase reporter.are known for only four family members, sequences are
available for dozens. We used maximum likelihood
(Yang et al., 1995) to determine ancestral amino acid
states and evolutionary changes in the H6-H7 residues
corresponding to Thr439, Glu440, and Phe443 in rodent
LRH-1 (TEF, Figure 8). These sites were chosen be-
cause, as discussed above, structural and experimen-
tal evidence indicates that they exclude or diminish
phospholipid binding in mLRH-1, but the homologous
residues, Ala, Gly, and Leu, confer ligand binding on
hLRH-1 and the SF-1s (AGL, Figure 8). The NR5A an-
cestral sequence has all three ligand-associated states
(AGL), and this reconstruction has extremely high confi-
dence (posterior probability 100% for each site). The
derived TEF residues that close the pocket in the ab-
sence of ligand all evolved much later on than the
branch leading to the rodent LRH-1 (posterior prob-
ability 100% for each site). Examination of the genetic
code indicates that each of these replacements can be
conferred by a single base-pair mutation.
These findings strongly corroborate the hypothesis
that ligand binding was ancestral in the SF-1/LRH-1
family and was later lost or radically diminished in ro-
dent LRH-1s due to a small number of specific aminoacid replacements. The lost or altered ligand binding
state in rodent LRH-1 is the second example of a taxon-
specific nuclear receptor losing the capacity to bind li-
gand from a liganded ancestor; the other is the estro-
gen receptor ortholog of the mollusc Aplysia californica
(Thornton et al., 2003). These findings cast doubt on
the hypothesis that ligand binding in the nuclear recep-
tor superfamily was independently gained numerous
times from an ancestral orphan receptor (Escriva et al.,
2000). If the loss of ligand dependence is common and
requires only a few sequence changes, the opposite
scenario—repeated loss of ligand binding from a li-
ganded ancestor—may better characterize NR evo-
lution.
Finally, the finding that the rodent LRH-1 has di-
verged from other members of the family is of interest
in light of differences noted in both bile acid and cho-
lesterol transport for humans and mice (Dietschy and
Turley, 2002). While species differences can be attrib-
uted to the absence of the murine cholesterol transport
protein (CETP) (Lie et al., 2002), there are notable differ-
ences in the regulation of LRH-1 targets (Cyp7A1,
Cyp8B, and SHP) involved in cholesterol homeostasis
(Delerive et al., 2004; Fayard et al., 2004).
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aThe maximum posterior probability phylogeny of the NR5 gene
family is shown, including LRH-1s (red), SF-1s (blue), and outgroup c
sequences (black, with number of sequences analyzed shown in d
parentheses). Residues homologous to mLRH-1 positions 439, 440, t
and 443 are shown for each LRH-1/SF-1 sequence (aa). Maximum
alikelihood reconstructions of ancestral amino acid states are shown
bfor SF-1 and LRH-1 proteins in the last common ancestor of verte-
tbrates (squares), of tetrapods (triangles), and of mammals (circles),
as well as for the common ancestral gene preceding the duplica- u
tion that split the SF-1 and LRH-1 lineages (star). All ancestral re- l
constructions have 100% posterior probability. Green arrowhead r
shows acquisition of amino acids that exclude ligand in the rodent
nLRH-1 lineage and loss of ligand binding on the same branch. Spe-
cies names and accession numbers are provided in Supplemental
ETable S2.
P
T
3Do LRH-1/SF-1 Function as Nuclear
fPhospholipid Sensors?
wThat the bacterial phospholipid (PG) adopts an iden-
btical conformation, filling both hLRH-1 and SF-1 pock-
a
ets equally well, offers a strong structural argument that H
this “fortuitous” ligand resembles closely the native li- p
pgand. Furthermore, phosphatidyl inositols shown here
zto bind NR5A receptors are predicted to adopt a similar
pconformation. Thus, our collective structural and bio-
cchemical data support phospholipids as ligands for
P
both SF-1 and hLRH-1; this result is unexpected given w
the role that each plays in cholesterol transport or cho- A
alesterol metabolism in sterol synthesis. This proposalmplies that a distinct pool of cellular lipids signal via
odulation of the NR5A nuclear receptors. Indeed, the
iterature suggests that nuclear phosphatidyl inositol
ipids exist as well as enzymes affecting their metabo-
ism, such as phosphatidyl inositol 3-kinase (PI-3K) (Ir-
ine, 2002; Ledeen and Wu, 2004; Martelli et al., 2003).
dditionally, both PI-3 and PI-5 phosphatases exhibit
rominent nuclear staining (Bacqueville et al., 2001; De-
eris et al., 2003), thus providing a mechanism to down-
egulate PI nuclear signaling. Although we found that
ortmannin (PI-3 kinase inhibitor) and the PI-3 phos-
hatase PTEN affected the activities of wild-type and
ocket mutant SF-1 receptors differently (I.N.K., unpub-
ished data), further studies and additional pharmaco-
ogical tools are needed to selectively disrupt nuclear
hospholipid signaling pathways. Nonetheless, the link
etween PI-3 kinase signaling and NR5A receptor ac-
ivity is intriguing given the roles that both SF-1 and
RH-1 play in cell proliferation. Indeed, haploinsuffi-
iency of both sf-1 and lrh-1 leads to decreased cell
roliferation (Bland et al., 2000; Botrugno et al., 2004),
hile increased gene dosage of SF-1 is reported to be
ssociated with human adrenal cortical tumors (de Fi-
ueiredo et al., 2004). Because PI-3 kinase pathways
re known to regulate cell cycle progression and cell
rowth, it is tempting to speculate that extracellular
vents that trigger this pathway might also elevate
uclear PIs, and thus modulate SF-1/LRH-1 activities.
Finally, it is worth considering how phospholipids are
elivered to nuclear receptors. Cytoplasmic shuttling of
Is to the plasma membrane is carried out by phospha-
idyl inositol transport proteins (PITP) in an ATP-inde-
endent manner; these proteins are also present in the
ucleus. Crystal structures of phospholipid binding
roteins show a large hydrophobic pocket or tunnel
ble to bind lipids (Yoder et al., 2001; Hsuan and Cock-
roft, 2001; Soccio and Breslow, 2003). Whether PIs are
irectly taken up by SF-1/LRH-1 from membranes (due
o transient receptor shuttling between the cytoplasm
nd nucleus) or are delivered by nuclear phospholipid
inding proteins remains unclear. While many ques-
ions are still to be answered, our current study leads
s to hypothesize phosphatidyl inositols as bona fide
igands for NR5A receptors and, as such, provide a di-
ect link between transcription and phospholipid sig-
aling.
xperimental Procedures
rotein Purification and Crystallization
he mSF-1 LBD (219–462) was engineered by mutating cysteines at
02, 408, 413, and 423 to prevent oxidation (mSF-1 residue number
ollows accession NP_620639). Modified HIS6-tagged mSF-1 LBD
as expressed and purified by Ni-Trap affinity purification followed
y cleavage of HIS-tag with recombinant tobacco etch viral prote-
se, as previously described for mLRH-1 LBD (Sablin et al., 2003).
IS6-tagged hSF-1 (222–461) and hLRH-1 (300–542) were ex-
ressed using the pRSETa vector, purified by Ni-NTA chromatogra-
hy, followed by cleavage of the HIS6-tag using thrombin. Crystalli-
ation conditions for hSF-1 with and without the coactivator
eptide TIF-2 are described in detail in Madauss et al. (2004), and
rystals were obtained in 0.1 M TRIS (pH 7.8), 0.4 M MgCl2, 13%
EG6000, 5 mM DTT. For mSF-1, equal volumes of mSF-1 LBD
ere added to a 6-fold molar excess of mSHP-1 peptide (RPTILY-
LLSPSPR) in 14% PEG8K, 0.1 M TRIS (pH 7.5), 5% isopropanol,
nd 15% xylitol to produce in 5 days large (200 µm) crystals that
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353diffracted to 1.1–1.2 Å. Data were integrated using DENZO and
scaled with SCALEPACK. For hLRH-1, the protein and TIF-2 pep-
tide were mixed in equal volumes with 1.2 M sodium potassium
phosphate (pH 4.9), 4% (v/v) glycerol, 4% (v/v) ethylene glycol.
Crystals were grown at 22°C and appeared in one week and
reached 100–200 m in each dimension over a period of 3 weeks.
Prior to data collection, hLRH-1 crystals were dipped in cryopro-
tectant (reservoir solution containing 11.5% glycerol and 11.5%
ethylene glycol) and flash-frozen in liquid nitrogen. The TIF-2 pep-
tide sequence is KENALLRYLLDKDD and was used for both hLRH-1
and hSF-1 crystallization. X-ray data were collected at IMCA 17-ID
line (Argonne, Illinois), and data were processed and scaled with
HKL2000. The hLRH-1 model was built by molecular replacement
with Amore program using hSF-1 as a search model and refined
with CNS. In this model, a second TIF-2 peptide is found in the
asymmetric unit and forms loose contacts with the tail of the first
TIF-2 peptide positioned in the coactivator cleft formed by H3, H4,
and H12 of the hLRH-1 receptor. Rebuilding between rounds of
refinement was performed with the graphics program QUANTA.
Cell Culture and Transfections
Human HepG2 liver carcinoma cells were plated the day of trans-
fection in 24 well plates and transfected with FUGENE 6 with
amounts of DNA indicated in figures and legends. For all experi-
ments, 200 ng/well of luciferase reporter were used and pCI-Neo-
β-gal (50 ng/well) were transfected along with wild-type or mutant
receptors. Luciferase activity was measured after 48 hr, as pre-
viously described (Sablin et al., 2003). Expression of all mutants
was tested by Western blot analyses using anti-HA antibody (Co-
vance) directed against an N-terminal tag. In all cases, mutant re-
ceptors were expressed at equivalent or higher levels than wild-
type protein. For N-butanol experiments, 0.1% 1-butanol was
added for 2 hr. All transfection experiments were done in triplicates
and repeated at least three times; representative experiments are
shown with standard errors indicated by bars.
Ligand Analyses and Phospholipid Binding Assays
Protein samples were desalted and injected onto a column packed
with P6 gel (BioRad) to exchange nonvolatile buffers with 20 mM
ammonium acetate (pH 6.8). Buffer-exchanged protein was col-
lected and back flushed at a flow rate of 0.75–1 µl/min into a na-
noflow electrospray ionization source fitted on a Waters/Micromass
QTOF-1 (Beverly, Massachusetts) mass spectrometer. Data were col-
lected in positive ion mode over a mass range of 1000–4000 m/z. For
structural determination of ligands, a similar in-gel filtration appara-
tus was connected to an orthogonal acceleration time-of-flight
mass spectrometer (LCMSD-TOF, Agilent) and a quadrupole ion
trap mass spectrometer (LCMSD Trap SL, Agilent). Samples were
examined utilizing negative ion electrospray using conditions that
denatured the protein-ligand complex.
PIP StripsTM (Echelon) were first blotted for 1 hr with Casein hy-
drolysate (Sigma) dissolved in TBST buffer. HIS6-tagged LBD pro-
teins were added at a concentration of 1.5 M and incubated at
4°C overnight, followed by incubation at 25°C for 4 hr. Proteins were
detected with rabbit polyclonal anti-His antibody (Immunology Con-
sultants Laboratory). For liposome preparations, lipids (4 µM) were
mixed in chloroform/methanol and dried under reduced pressure
to form a lipid film. Lipids were as follows: 1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphate (PA) and 1-palmitoyl-2-oleoyl-sn-glycero-
3-phosphocholine (PC) were from Avanti Polar Lipids (Alabaster,
Alabama), and 1,2-dipalymitoyl-sn-glycero-3-phosphoinositol 3,4-
bisphosphate (PI(3,4)P2) and 1,2-dipalymitoyl-sn-glycero-3-phos-
phoinositol 3,4,5-trisphosphate (PI(3,4,5)P3) were from Echelon
Biosciences Inc (Salt Lake City, Utah). Liposomes were formed at
pH 7.6 TRIS buffered saline by vortexing and immersed in a bath
sonicator for 1–2 hr under argon at room temperature to facilitate
formation of uniformly mixed small unilamellar vesicles. Particle
zeta average size was determined using a Malvern (Southborough,
Massachusetts) Zeta3000 Dynamic Light Scattering Instrument.
Neutral liposomes were prepared with 100% PC and found to be
70.6 ± 0.4 nm. All other liposomes were prepared at a lipid ratio of
PC:nonPC [9:1] and found to be 46.4 ± 1.4 nm for PC:PA, 37.1 ±
3.8 nm for PC:PI(3,4)P , and 31.2 ± 1.4 nm for PC:PI(3,4,5)P . Under2 3these conditions, PI and PA lipids should mix completely into sta-
ble bilayers and consist primarily of PC. LBD proteins (2 mg/ml)
were exchanged into liposome buffer and combined with the lipo-
somes to produce a 25:1 molar ratio of PC to protein and a 2.5:1
molar ratio of PA, PI(3,4)P2, or PI(3,4,5)P3 to protein. Mixtures were
incubated for 20 hr at room temperature, and protein was sepa-
rated from liposomes by gel-filtration on Superdex 75 (Pharmacia),
concentrated, subjected to another round of gel filtration, and ana-
lyzed by mass spectrometry as described above. The amount of
SF-1 LBD protein associated with free liposomes (void volume) fol-
lowing gel filtration was determined to be <1% for all liposome
species.
Peptide Binding Assays
LBD proteins were serially diluted from 150 µM to 0.002 µM in bind-
ing buffer (50 mM NaPO4, 150 mM NaCl, pH 7.2, 1 mM DTT, 1 mM
EDTA, 0.01% NP40, 10% glycerol). Diluted protein was added to
fluorescent coregulator peptide (20 nM) in 384 well plates yielding
final protein concentrations of 75–0.001 µM and 10 nM of fluores-
cent peptide. Samples were analyzed as previously described
(Moore et al., 2004). Construction of 20 aa coregulator peptides
with the general motif of CXXXXXXXLXXL/AL/AXXXXXXX were as
follows: peptides were synthesized in parallel using standard fluor-
enylmethoxycarbonyl (Fmoc) chemistry in 48 well synthesis blocks
(FlexChem System, Robbins) (Wellings and Atherton, 1997). Cou-
pling efficiency was monitored and the completed peptides were
cleaved from the resin, followed by reversed-phase chromatogra-
phy and mass spectrometry (MALDI-TOF/ESI) to purify the pep-
tides, and are described in Moore et al. (2004).
Evolutionary Analysis
Protein sequences of 48 SF-1/LRH-1/FtzF1 family members with
full-length ligand binding domains were obtained from GenBank by
BLAST search using Homo sapiens SF-1 as a query. Twenty addi-
tional sequences from the closely related ERR, GCNF/GRF, and
RXR groups (Thornton and DeSalle, 2000) were also obtained to
serve as outgroup sequences. (See Supplemental Table S2 for ac-
cession numbers and species names). These sequences were
aligned using ClustalX 1.83 software (Thompson et al., 1994) as-
suming a gap:change cost ratio of 10. The phylogeny of the gene
family was then inferred from the aligned sequences using the
Bayesian Markov Chain Monte Carlo method (Ronquist and
Huelsenbeck, 2003) implemented in MrBayes v. 3.0 software. Tree
and parameter space were explored with four simultaneous chains
(three heated) for 300,000 generations each, using the Jones model
of protein evolution with a four-category discrete γ model of
among-site rate variation. Priors were equal for tree topologies,
uniform (0,10) for branch lengths, and uniform (0.1, 5) for the α
shape parameter of the γ distribution. The initial 100,000 trees, a
point well past stationarity, were discarded as burn-in.
Phylogenetic reconstruction of the ancestral states at internal
nodes for ligand binding or ligand independence, coded as a binary
character, were conducted by parsimony and maximum likelihood.
For the former, we used Fitch’s parsimony algorithm (Fitch, 1971)
on a simple tree consisting of the four taxa for which ligand binding
states are known (Sablin et al., 2003; this paper). For maximum
likelihood reconstruction, we calculated the likelihood of each an-
cestral state 0 (no ligand binding) and 1 (ligand binding) as the
probability of evolving the terminal states in mLRH-1, hLRH-1,
mSF-1, and hSF-1, given the phylogeny that relates these genes,
and a simple reversible Markov process for transitions between
states 0 and 1 (Pagel, 1999). The probability Pij of observing a state
change on a tree branch of length k is Pij =
1
2
−
1
2
e−k.
Branch lengths were assumed equal a priori and scaled to their
maximum likelihood values by hill climbing; unknown states at in-
ternal nodes other than the NR5A ancestor were treated as nui-
sance parameters and optimized by maximum likelihood.
Ancestral amino acid states for positions in the sequence align-
ment corresponding to 439, 440, and 443 in mLRH-1 were recon-
structed using the marginal Bayesian maximum likelihood method
of Yang (Yang et al., 1995), as implemented in PAML 3.14 software,
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354assuming a Jones model of amino acid evolution and a four-cate- R
Hgory γ model of rate variation among sites (α optimized by ML). The
tree for ancestral state reconstruction was the maximum posterior (
Mprobability tree from the Bayesian analysis, adjusted at three nodes
that had posterior probability <0.95 to make them consistent with D
known taxonomic relationships among species (see Supplemental B
Figure S3). Branch lengths for the ancestral reconstruction were a
optimized by maximum likelihood using PAML software. a
D
B
Supplemental Data l
Supplemental Data include three figures and two tables and can 2
be found with this article online at http://www.cell.com/cgi/
Dcontent/full/120/3/343/DC1/.
h
o
fAcknowledgments
D
SWe would like to thank Drs. D. Julius, K. Shokat, D. Stokoe, S.
mWadekar, N. Jouravel, D. Moore, and F. Szoka for critical com-
2ments, experimental suggestions, and reagents. The IMCA-CAT
Dbeamline 17-ID (or 17-BM) at the Advanced Photon Source was
osupported by the companies of the Industrial Macromolecular
Crystallography Association through a contract with Illinois Insti- E
tute of Technology. We would like to thank Drs. Cheng Yang and n
Joseph Ferrara from Rigaku/MSC Inc. for an invitation to this facil- F
ity. This work was funded by NIH 1R21-GM70792-1 and the Oregon (
Medical Research Foundation to J.W.T., a HHMI predoctoral fellow- s
ship to J.A.M., and a NIDDK-PO1 support to R.J.F., R.K.G., and
FH.A.I.
p
s
Received: November 3, 2004 F
Revised: January 13, 2005 c
Accepted: January 27, 2005
HPublished: February 10, 2005
G
aReferences
n
HBacqueville, D., Deleris, P., Mendre, C., Pieraggi, M.T., Chap, H.,
dGuillon, G., Perret, B., and Breton-Douillon, M. (2001). Characteriza-
Ition of a G protein-activated phosphoinositide 3-kinase in vascular
Msmooth muscle cell nuclei. J. Biol. Chem. 276, 22170–22176.
rBaker, K.D., Shewchuk, L.M., Kozlova, T., Makishima, M., Hassell,
dA., Wisely, B., Caravella, J.A., Lambert, M.H., Reinking, J.L., Krause,
IH., et al. (2003). The Drosophila orphan nuclear receptor DHR38
smediates an atypical ecdysteroid signaling pathway. Cell 113,
731–742. I
aBillas, I.M., Moulinier, L., Rochel, N., and Moras, D. (2001). Crystal
istructure of the ligand-binding domain of the ultraspiracle protein
USP, the ortholog of retinoid X receptors in insects. J. Biol. Chem. K
276, 7465–7474. h
LBland, M.L., Jamieson, C.A., Akana, S.F., Bornstein, S.R., Eisen-
chofer, G., Dallman, M.F., and Ingraham, H.A. (2000). Haploinsuffi-
(ciency of steroidogenic factor-1 in mice disrupts adrenal develop-
ment leading to an impaired stress response. Proc. Natl. Acad. Sci. L
USA 97, 14488–14493. K
rBotrugno, O.A., Fayard, E., Annicotte, J.S., Haby, C., Brennan, T.,
UWendling, O., Tanaka, T., Kodama, T., Thomas, W., Auwerx, J., and
Schoonjans, K. (2004). Synergy between LRH-1 and beta-catenin L
induces G1 cyclin-mediated cell proliferation. Mol. Cell 15, 499– f
509. L
Christenson, L.K., McAllister, J.M., Martin, K.O., Javitt, N.B., Os- M
borne, T.F., and Strauss, J.F., 3rd. (1998). Oxysterol regulation of t
steroidogenic acute regulatory protein gene expression. Structural D
specificity and transcriptional and posttranscriptional actions. J. L
Biol. Chem. 273, 30729–30735. c
Darimont, B.D., Wagner, R.L., Apriletti, J.W., Stallcup, M.R., Kush- 1
ner, P.J., Baxter, J.D., Fletterick, R.J., and Yamamoto, K.R. (1998). L
Structure and specificity of nuclear receptor-coactivator interac- L
tions. Genes Dev. 273, 30729–30735. l
Jde Figueiredo, B.C., Cavalli, L.R., Pianovski, M.A., Lalli, E., Sandrini,., Ribeiro, R.C., Zambetti, G., Delacerda, L., Rodrigues, G.A., and
addad, B.R. (2004). Amplification of the steroidogenic factor 1
SF-1) gene in childhood adrenocortical tumors. J. Clin. Endocrinol.
etab. Published online November 2004. 10.1210/jc.2004-0942
eleris, P., Bacqueville, D., Gayral, S., Carrez, L., Salles, J.P., Perret,
., and Breton-Douillon, M. (2003). SHIP-2 and PTEN are expressed
nd active in vascular smooth muscle cell nuclei, but only SHIP-2 is
ssociated with nuclear speckles. J. Biol. Chem. 278, 38884–38891.
elerive, P., Galardi, C.M., Bisi, J.E., Nicodeme, E., and Goodwin,
. (2004). Identification of liver receptor homolog-1 as a novel regu-
ator of apolipoprotein AI gene transcription. Mol. Endocrinol. 18,
378–2387.
esclozeaux, M., Krylova, I.N., Horn, F., Fletterick, R.J., and Ingra-
am, H.A. (2002). Phosphorylation and intramolecular stabilization
f the ligand binding domain in the nuclear receptor steroidogenic
actor 1. Mol. Cell. Biol. 22, 7193–7203.
he-Paganon, S., Duda, K., Iwamoto, M., Chi, Y.I., and Shoelson,
.E. (2002). Crystal structure of the HNF4 alpha ligand binding do-
ain in complex with endogenous fatty acid ligand. J. Biol. Chem.
77, 37973–37976.
ietschy, J.M., and Turley, S.D. (2002). Control of cholesterol turn-
ver in the mouse. J. Biol. Chem. 277, 3801–3804.
scriva, H., Delaunay, F., and Laudet, V. (2000). Ligand binding and
uclear receptor evolution. Bioessays 22, 717–727.
ang, Y., Vilella-Bach, M., Bachmann, R., Flanigan, A., and Chen, J.
2001). Phosphatidic acid-mediated mitogenic activation of mTOR
ignaling. Science 294, 1942–1945.
ayard, E., Auwerx, J., and Schoonjans, K. (2004). LRH-1: an or-
han nuclear receptor involved in development, metabolism and
teroidogenesis. Trends Cell Biol. 14, 250–260.
itch, W.M. (1971). Toward defining the course of evolution: minimal
hange for a specific tree topology. Syst. Zool. 20, 406–416.
olter, E., Kotaja, N., Makela, S., Strauss, L., Kietz, S., Janne, O.A.,
ustafsson, J.A., Palvimo, J.J., and Treuter, E. (2002). Inhibition of
ndrogen receptor (AR) function by the reproductive orphan
uclear receptor DAX-1. Mol. Endocrinol. 16, 515–528.
suan, J., and Cockcroft, S. (2001). The PITP family of phosphati-
ylinositol transfer proteins. Genome Biol. 2, REVIEWS3011.
ngraham, H.A., Lala, D.S., Ikeda, Y., Luo, X., Shen, W.H., Nachtigal,
.W., Abbud, R., Nilson, J.H., and Parker, K.L. (1994). The nuclear
eceptor steroidogenic factor 1 acts at multiple levels of the repro-
uctive axis. Genes Dev. 8, 2302–2312.
rvine, R.F. (2002). Nuclear lipid signaling. Sci. STKE, http://stke.
ciencemag.org/cgi/content/full/OC_sigtrans;2002/150/re13.
to, M., Yu, R., and Jameson, J.L. (1997). DAX-1 inhibits SF-1-medi-
ted transactivation via a carboxy-terminal domain that is deleted
n adrenal hypoplasia congenita. Mol. Cell. Biol. 17, 1476–1483.
allen, J.A., Schlaeppi, J.M., Bitsch, F., Geisse, S., Geiser, M., Del-
on, I., and Fournier, B. (2002). X-ray structure of the hRORalpha
BD at 1.63 A. Structural and functional data that cholesterol or a
holesterol derivative is the natural ligand of RORalpha. Structure
Camb.) 10, 1697–1707.
ala, D.S., Syka, P.M., Lazarchik, S.B., Mangelsdorf, D.J., Parker,
.L., and Heyman, R.A. (1997). Activation of the orphan nuclear
eceptor steroidogenic factor 1 by oxysterols. Proc. Natl. Acad. Sci.
SA 94, 4895–4900.
edeen, R.W., and Wu, G. (2004). Nuclear lipids: key signaling ef-
ectors in the nervous system and other tissues. J. Lipid Res. 45, –.
ee, M.K., Lebedeva, L., Suzawa, M., Wadekar, S., Desclozeaux,
., and Ingraham, H.A. (2005). Repression of orphan nuclear recep-
or activity via SUMO-modification and the Dead-Box Protein
P103 (Ddx20, Gemin-3). Mol. Biol. Cell 25, 1879–1890.
i, Y., Lambert, M.H., and Xu, H.E. (2003). Activation of nuclear re-
eptors: a perspective from structural genomics. Structure (Camb.)
1, 741–746.
ie, J., de Crom, R., van Gent, T., van Haperen, R., Scheek, L.,
ankhuizen, I., and van Tol, A. (2002). Elevation of plasma phospho-
ipid transfer protein in transgenic mice increases VLDL secretion.
. Lipid Res. 43, 1875–1880.
Phospholipids as NR5A Receptor Ligands
355Lu, T.T., Makishima, M., Repa, J.J., Schoonjans, K., Kerr, T.A., Au-
werx, J., and Mangelsdorf, D.J. (2000). Molecular basis for feed-
back regulation of bile acid synthesis by nuclear receptors. Mol.
Cell 6, 507–515.
Ludbrook, L.M., and Harley, V.R. (2004). Sex determination: a ‘win-
dow’ of DAX1 activity. Trends Endocrinol. Metab. 15, 116–121.
Luo, X., Ikeda, Y., and Parker, K.L. (1994). A cell-specific nuclear
receptor is essential for adrenal and gonadal development and sex-
ual differentiation. Cell 77, 481–490.
Madauss, K., Juzumiene, D., Waitt, G., Williams, J.P., and Williams,
S.P. (2004). Generation and characterization of human steroido-
genic factor 1 LBD crystals with and without bound co-factor pep-
tide. Endocr. Res. 30, 775–785.
Martelli, A.M., Tabellini, G., Borgatti, P., Bortul, R., Capitani, S., and
Neri, L.M. (2003). Nuclear lipids: new functions for old molecules?
J. Cell. Biochem. 88, 455–461.
Mellon, S.H., and Bair, S.R. (1998). 25-Hydroxycholesterol is not a
ligand for the orphan nuclear receptor steroidogenic factor-1 (SF-
1). Endocrinology 139, 3026–3029.
Moore, J.M., Galicia, S.J., McReynolds, A.C., Nguyen, N.H., Scan-
lan, T.S., and Guy, R.K. (2004). Quantitative proteomics of the thy-
roid hormone receptor-coregulator interactions. J. Biol. Chem. 279,
27584–27590.
Nachtigal, M.W., Hirokawa, Y., Enyeart-VanHouten, D.L., Flanagan,
J.N., Hammer, G.D., and Ingraham, H.A. (1998). Wilms’ tumor 1 and
Dax-1 modulate the orphan nuclear receptor SF-1 in sex-specific
gene expression. Cell 93, 445–454.
Pagel, M. (1999). Inferring the historical patterns of biological evo-
lution. Nature 401, 877–884.
Ronquist, F., and Huelsenbeck, J.P. (2003). MrBayes 3: Bayesian
phylogenetic inference under mixed models. Bioinformatics 19,
1572–1574.
Sablin, E.P., Krylova, I.N., Fletterick, R.J., and Ingraham, H.A.
(2003). Structural basis for ligand-independent activation of the or-
phan nuclear receptor LRH-1. Mol. Cell 11, 1575–1585.
Soccio, R.E., and Breslow, J.L. (2003). StAR-related lipid transfer
(START) proteins: mediators of intracellular lipid metabolism. J.
Biol. Chem. 278, 22183–22186.
Steinmetz, A.C., Renaud, J.P., and Moras, D. (2001). Binding of li-
gands and activation of transcription by nuclear receptors. Annu.
Rev. Biophys. Biomol. Struct. 30, 329–359.
Thompson, J.D., Higgins, D.G., and Gibson, T.J. (1994). CLUSTALW:
Improving the sensitivity of progressive multiple sequence align-
ment through sequence weighting, position-specific gap penalties
and weight matrix choice. Nucleic Acids Res. 22, 4673–4680.
Thornton, J.W., and DeSalle, R. (2000). A new method to localize
and test the significance of incongruence: detecting domain shuf-
fling in the nuclear receptor superfamily. Syst. Biol. 49, 183–201.
Thornton, J.W., Need, E., and Crews, D. (2003). Resurrecting the
ancestral steroid receptor: ancient origin of estrogen signaling. Sci-
ence 301, 1714–1717.
Wang, Z., Benoit, G., Liu, J., Prasad, S., Aarnisalo, P., Liu, X., Xu,
H., Walker, N.P., and Perlmann, T. (2003). Structure and function of
Nurr1 identifies a class of ligand-independent nuclear receptors.
Nature 423, 555–560.
Weatherman, R.V., Fletterick, R.J., and Scanlan, T.S. (1999).
Nuclear-receptor ligands and ligand-binding domains. Annu. Rev.
Biochem. 68, 559–581.
Wellings, D.A., and Atherton, E. (1997). Standard Fmoc protocols.
Methods Enzymol. 289, 44–67.
Wisely, G.B., Miller, A.B., Davis, R.G., Thornquest, A.D., Jr., John-
son, R., Spitzer, T., Sefler, A., Shearer, B., Moore, J.T., Willson, T.M.,
and Williams, S.P. (2002). Hepatocyte nuclear factor 4 is a transcrip-
tion factor that constitutively binds fatty acids. Structure (Camb.)
10, 1225–1234.
Yang, Z., Kumar, S., and Nei, M. (1995). A new method of inference
of ancestral nucleotide and amino acid sequences. Genetics 141,
1641–1650.
Yoder, M.D., Thomas, L.M., Tremblay, J.M., Oliver, R.L., Yarbrough,L.R., and Helmkamp, G.M., Jr. (2001). Structure of a multifunctional
protein. Mammalian phosphatidylinositol transfer protein com-
plexed with phosphatidylcholine. J. Biol. Chem. 276, 9246–9252.
Accession Numbers
Coordinates have been deposited in the Protein Data Bank as
follows: mSF-1 PDB ID 1YMT, RCSB code RCSB031696, hLRH-1
PDB ID 1YOK and RCSB031753, and hSF-1 PDB ID 1YOW and
RCSB031764.
